Clinical trial Recruiting at 1 site Phase2; Phase3 Interventional Ages 18 to 80

Transcutaneous Electrical Acupoint Stimulation at Hand Jing-Well Points for Disorders of Consciousness

Official title: Efficacy and Safety of Transcutaneous Electrical Acupoint Stimulation at Hand Jing-Well Points in Patients With Disorders of Consciousness:A Multicenter Randomized Controlled Trial

Run by Xijing Hospital · NCT07535593 · Data updated 2026-11-12

We test a noninvasive electrical stimulation at hand points to see if it can help people who have altered consciousness after severe brain injury.

Quick facts

PhasePhase2; Phase3
Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment160 (estimated)
SponsorXijing Hospital
Academic / other
Locations1 site (Xi'an, Shaanxi)
StatusRecruiting
StartedApril 20, 2026
Main results expectedJune 2028
Study endsDecember 2028
Registry record updatedAugust 5, 2026
Trial IDNCT07535593 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18-80 who are within 7-90 days after severe brain injury and diagnosed with VS/UWS or MCS (via CRS-R) and have intact hand skin.

Probably not a fit

Patients with progressive neurological disorders, epilepsy, unstable health, certain implanted devices, or concurrent use of specific medications may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter trial tests whether transcutaneous electrical acupoint stimulation (TEAS) at the twelve hand Jing-Well points can improve consciousness in adults with disorders of consciousness after severe brain injury. It compares TEAS to sham stimulation in a randomized, controlled design with blinded endpoint assessment. The study builds on prior signals suggesting possible benefit but aims to provide more robust evidence. Eligible participants are adults 18-80 within 7-90 days of injury, diagnosed with VS/UWS or MCS, and with intact hand skin. Exclusion criteria include active sedatives or certain neurological conditions, unstable health, implanted electronic devices, or pregnancy.

Why it matters

Potential benefit: If successful, TEAS could offer a noninvasive option to help regain consciousness in some patients with DoC.

How similar studies have gone: Previous multicenter work (Wells-DoC) suggested possible improvements but did not achieve statistical significance, so robust confirmation is needed.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age: 18-80 years old;
* From 7 to 90 days since brain injury;
* Diagnosed in VS/UWS or MCS as defined by at least two CRS-R assessments performed during the screening period
* Acquired cerebral damage of known etiology
* Intact hand skin
* Informed consent given by the legal surrogate

Exclusion Criteria:

* Patients who continuously receive sedative drugs and Na+ or Ca2+ channel blockers (e.g., carbamazepine) or NMDA receptor antagonists (e.g., dextromethorphan)
* History of previous serious、progressive neurological disorder prior to the brain injury;
* Epilepsy and seizure
* Unstable vital signs or life-threatening comorbidities
* Implanted devices: including cardiac pacemakers or implantable cardioverter-defibrillators (ICDs), deep brain stimulators, ventriculoperitoneal (VP) shunts, and other indwelling electronic or neurosurgical implants.
* Documented pregnancy

Where it's running

  • Xijing Hospital
    Xi'an, Shaanxi, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.